All In Biotech

Drug Trial Radar · NCT06902519

Study of GS-0151 in Participants With Rheumatoid Arthritis

A Phase 1b, Randomized, Blinded, Placebo-Controlled, Multicenter Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of GS-0151 in Adult Participants With Rheumatoid Arthritis

Last checked: Nov 20, 2026Latest source record: Sep 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

65

Actual

Start

May 14, 2025

Primary completion

Mar 2027

Study completion Mar 2027

Sponsor

Lead sponsor
Gilead SciencesGilead Sciences (GILD)
Sponsor type
Industry
First posted
Mar 30, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical study is to learn more about the study drug GS-0151. The study is done to find how safe, well-tolerated the drug is. This will also assess how the drug is absorbed, modified, distributed and cleared from the body (the pharmacokinetics (PK) of the drug), when given multiple times to participants with rheumatoid arthritis (RA). The primary objectives of this study is to assess the safety and tolerability of multiple ascending doses of GS-0151 in participants with RA and to characterize the PK of GS-0151 following multiple doses of GS-0151 in participants with RA.

Conditions

  • Rheumatoid Arthritis

Interventions

  • GS-0151Drug

    Administered for 12 weeks

  • PlaceboDrug

    Administered for 12 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Cohort 1, 2 and 3: Percentage of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs)Time frame: First dose up to 19 Weeks post end of treatment at Week 12
  2. Cohort 1, 2 and 3: Percentage of Participants Experiencing Treatment-Emergent Laboratory AbnormalitiesTime frame: First dose up to 19 Weeks post end of treatment at Week 12
  3. Cohorts 1, 2 and 3: Percentage of Participants Experiencing Serous Adverse Events (SAEs) and Adverse Events (AEs) Leading to Study DiscontinuationTime frame: First dose up to 19 Weeks post end of treatment at Week 12
  4. Cohort 1, 2 and 3: Serum AUCtau Following the Last Dose of GS-0151Time frame: Up to Week 12
  5. Cohorts 1, 2 and 3: Serum Cmax, Following the Last Dose of GS-0151Time frame: Up to Week 12
  6. Cohorts 1, 2 and 3: Serum Tmax Following the Last Dose of GS-0151Time frame: Up to Week 12

Locations

35 sites in 6 countries. Site status is shown where the registry gives one.

  • Pinnacle Research Group, LLC

    Anniston, Alabama

  • University of California, San Diego

    La Jolla, California

  • Stanford University School of Medicine

    Palo Alto, California

  • Medvin Clinical Research

    Tujunga, California

  • Medvin Clinical Research

    Whittier, California

  • Clinical Research of West Florida, Inc

    Clearwater, Florida

  • Great Lakes Clinical Trials dba Flourish Research Chicago

    Chicago, Illinois

  • Accurate Clinical Research, Inc

    Lake Charles, Louisiana

  • Lynn Health Science Institute

    Oklahoma City, Oklahoma

  • Altoona Center for Clinical Research

    Duncansville, Pennsylvania

  • Accurate Clinical Management, LLC

    Baytown, Texas

  • Precision Comprehensive Clinical Research Solutions

    Colleyville, Texas

  • Accurate Clinical Research, Inc

    Houston, Texas

  • Precision Comprehensive Clinical Research Solutions

    Irving, Texas

  • Southwest Rheumatology Research

    Mesquite, Texas

  • Clinical Trials of Texas LLC, dba Flourish Research

    San Antonio, Texas

  • DM Clinical Research

    Tomball, Texas

  • Tidewater Clinical Research, LLC/ Virginia Rheumatology Clinic

    Virginia Beach, Virginia

  • ARENSIA Exploratory Medicine, LLC

    Tbilisi, Georgia

  • Universitatsklinikum Koln

    Cologne, Germany

  • Krakenhaus Porz am Rhein

    Cologne, Germany

  • Hamburger Rheuma Forschungszentrum II

    Hamburg, Germany

  • Klinikum der Universitat Munchen

    München, Germany

  • Republican Clinical Hospital "Timofei Mosneaga," Arensia EM

    Chisinau, Moldova

  • Clinicmed Daniluk

    Bialystok, Poland

  • FutureMeds Gydinia

    Gdynia, Poland

  • FutureMeds Lodz

    Lodz, Poland

  • MICS Centrum Medyczne Torun

    Torun, Poland

  • FutureMeds Targowek

    Warszawa Targówek, Poland

  • FutureMeds Wroclaw

    Wroclaw, Poland

  • Complejo Hospitalario Universitario A Coruna

    A Coruña, Spain

  • Hospital del Mar

    Barcelona, Spain

  • Hospital Universitario Ramon y Cajal

    Madrid, Spain

  • Hospital Universitari Parc Tauli

    Sabadell, Spain

  • Hospital Quironsalud Infanta Luisa

    Seville, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.